Clinical trials: Exacerbations
Cystic Fibrosis (CF), Type 2 Inflammatory Disorders
Type 2 Inflammation in Adults With Cystic Fibrosis
The goal of this observational study is to better understand why some adults with cystic fibrosis (CF) continue to have repeated pulmonary exacerbations, or episodes of worsening respiratory symptoms, despite treatment with…
- Trial name
- NCT07892443
- Volunteers
- 100 people
- Sponsor
- University of Virginia
Bronchiectasis, Immunoglobulin Subclass Deficiency
Immunoglobulin Replacement Therapy for Immunoglobulin G Subclass 2 Deficient Patients With Bronchiectasis
Bronchiectasis is a common chronic lung condition where patients have permanent airways damage leading to daily symptoms of cough, sputum production and recurrent respiratory tract infections.
- Trial name
- NCT03737617
- Testing
- Cuvitru 20 % Injectable Solution
- Where
- United Kingdom
- Sponsor
- University of Edinburgh
Cystic Fibrosis
Effectiveness of Respiratory Physiotherapy on Frequency of Exacerbations, Lung Function and Quality of Life After 6 Months in Children With Cystic Fibrosis
Daily respiratory physiotherapy is a fundamental part of cystic fibrosis treatment, however, patients adherence is low. Thus, there is a need for studies that evaluate the impact of physiotherapy supervision in patients with…
- Trial name
- NCT07088614
- Testing
- Remote respiratory physiotherapy
- Where
- Chile
- Volunteers
- 9 people
- Sponsor
- University of Americas - Chili
Cystic Fibrosis
Streamlined Treatment of Pulmonary Exacerbations in Pediatrics
The STOP PEDS RCT is a multicenter, parallel, open label randomized controlled trial evaluating the long-term (one year) and short-term safety and efficacy of two antibiotic treatment strategies for the management of outpatient…
- Trial name
- STOP PEDS RCT (NCT06654752)
- Testing
- Immediate Oral Antibiotics, Tailored Treatment: Oral Antibiotics only if Additional Treatment needed
- Where
- 33 sites in United States, Canada
- Volunteers
- 430 people
- Sponsor
- University of Washington, the Collaborative Health Studies Coordinating Center
Asthma
Home Telemonitoring of Resting Spontaneous Breathing in Severe Asthma: a Pilot Study
Asthma exacerbations account for a significant morbidity and disproportionate health care costs. However, there is no currently available biomarker or lung function parameter that can accurately predict the risk of future…
- Trial name
- AsthmaDom (NCT02990247)
- Testing
- anharmonic morphological analysis of the respiratory signals (AMARS)
- Where
- 2 sites in France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Bordeaux
Airway Auto Immunity in Asthma
IL-13 Blockade and Airway Autoimmunity in Asthma
It has been observed that certain section of patients having severe to moderate Asthma, do not benefit from oral corticosteroids and IL-5 blocking biologics.
- Trial name
- IL-SAA (NCT05564078)
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- McMaster University
Chronic Obstructive Pulmonary Disease
Real-life Effectiveness and Cost-effectiveness of Qvar Versus FP and BDP in the Management of COPD
The objective of this study is to compare the effectiveness, cost-effectiveness and direct healthcare costs of managing chronic obstructive pulmonary disease (COPD) in primary care patients with evidence of COPD who either…
- Trial name
- QvarCOPD (NCT01141452)
- Testing
- Extra-fine hydrofluoroalkane beclomethasone MDI, Chlorofluorocarbon beclomethasone metered dose inhaler, Fluticasone propionate metred dose inhaler
- Where
- United Kingdom
- Volunteers
- 815,377 people
- Sponsor
- Research in Real-Life Ltd
Generalized Pustular Psoriasis
A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular Psoriasis
This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study, all subjects need to use TQH2929 injection/placebo.
- Trial name
- NCT07314060
- Testing
- TQH2929 Injections
- Where
- 31 sites in China
- Volunteers
- 36 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Bronchiectasis
Tayside Rehabilitation in Bronchiectasis Exacerbations (TRIBE) : a Randomized Controlled Trial
Pulmonary rehabilitation is well established as a treatment in COPD. After exacerbations of COPD, rehabilitation is associated with reduced frequency of exacerbations and improved exercise capacity.
- Trial name
- TRIBE (NCT02179983)
- Testing
- Pulmonary rehabilitation
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- NHS Tayside
Sarcoidosis
Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS)
Pulmonary sarcoidosis patients with fibrosis often develop recurrent episodes of bronchitis. These can lead to worsening of disease for both the short and long term.
- Trial name
- REFS (NCT01830959)
- Testing
- Roflumilast
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Cincinnati
Pulmonary Disease, Chronic Obstructive, Exacerbation COPD
Respiratory Microbiome and COPD Exacerbations (RESMECOPD)
The global objective of this coordinated project is to test the following hypotheses: 1) the lung microbiome in chronic obstructive pulmonary disease (COPD) is different in patients suffering from frequent exacerbations (FE)…
- Trial name
- RESMECOPD (NCT03432234)
- Testing
- Biomarkers
- Where
- 6 sites in Spain
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Corporacion Parc Tauli
Pulmonary Disease, Chronic Obstructive
Changes in Heart Rate Variability And Heart Rate/Activity Slope After Hospitalization for Acute Exacerbations of COPD
The purpose of this study is to observe the variation in time between heart beats and how heart rate changes during activity evolve after hospitalization for an exacerbation of COPD.
- Trial name
- CHARM COPD (NCT05290831)
- Testing
- VitalPatch
- Volunteers
- 45 people
- Sponsor
- Minneapolis Veterans Affairs Medical Center
Asthma
Residual Exacerbations With Mepolizumab
This will be a two-year prospective study to characterize the nature of the remaining asthma exacerbations in patients treated with mepolizumab.
- Trial name
- NCT04578171
- Testing
- Mepolizumab
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Laval University
Chronic Obstructive Pulmonary Disease
Study on the Effects and Mechanisms of Modified Ma Xing Shi Gan Decoction in Treating Acute Exacerbations of Chronic Obstructive Pulmonary Disease
This study adopted a multi-center, randomized, controlled trial design. Patients with acute exacerbation of chronic obstructive pulmonary disease who met the inclusion criteria were randomly assigned to the experimental group and…
- Trial name
- NCT07403032
- Testing
- modified Ma Xing Shi Gan Decoction, The specific drug comes from "Chinese Expert Consensus on the Diagnosis and Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease (Revised Edition 2023)" and the GOLD guidelines
- Volunteers
- 200 people
- Sponsor
- Cuiling Feng
Asthma
European Cost of Asthma Treatment
The economic cost of asthma is considerable both in terms of direct medical costs (such as the cost of pharmaceuticals and hospital admissions) and indirect medical costs (such as time lost from work and premature death).
- Trial name
- EU-COAST (NCT01376219)
- Testing
- asthma control test
- Where
- Spain
- Volunteers
- 2,752 people
- Sponsor
- GlaxoSmithKline
Bronchiectasis Adult, Bronchiectasis With Acute Exacerbation
A Rhinovirus Challenge Study to Investigate Exacerbations and Immune Responses in Bronchiectasis
The goal of this study is to determine if viral infection with the common cold leads to an exacerbation in participants with bronchiectasis.
- Conditions
- Bronchiectasis Adult, Bronchiectasis With Acute Exacerbation, Bronchiectasis With Chronic Infection With Pseudomonas Aeruginosa, Viral Infection
- Trial name
- BARRIER (NCT06931002)
- Testing
- Rhinovirus A-16 Infection
- Where
- United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Chronic Obstructive Pulmonary Disease
Granzymes and Perforin at the Onset of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations
COPD exacerbations are characterized by an excessive accumulation and activation of inflammatory cells in the airways. It is not known whether this phenomenon represents a risk for for lung damage via the release in the…
- Trial name
- NCT00883701
- Where
- Greece
- Volunteers
- 30 people
- Sponsor
- University of Thessaly
Asthma
The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations
This study is looking at the effects of certain long-acting bronchodilators on patients with asthma who have specific genetic variations.
- Trial name
- GABLE (NCT00706446)
- Testing
- tiotropium bromide, Salmeterol, Formoterol
- Where
- 2 sites in United States
- Volunteers
- 255 people
- Sponsor
- Brigham and Women's Hospital
Myasthaenia Gravis, Myasthenia
Myasthenia Gravis Foundation of America Global MG Patient Registry
The goal of this observational study is to learn about the experiences of people living with Myasthenia Gravis (MG) in the United States.
- Conditions
- Myasthaenia Gravis, Myasthenia, Myasthenia Gravis Associated with Thymoma, Myasthenia Gravis Crisis
- Trial name
- MGFAPR (NCT06617741)
- Where
- United States
- Volunteers
- 3,800 people
- Sponsor
- Myasthenia Gravis Foundation of America
Chronic Obstructive Pulmonary Disease, COPD
Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations
ROMEO is a Phase III, multicentre, open-label, chronic-dosing extension study evaluating the long-term safety of two dose regimens of tozorakimab in participants with COPD and a history of exacerbations.
- Trial name
- ROMEO (NCT07566195)
- Testing
- Tozorakimab Dose Regimen 1, Tozorakimab Dose Regimen 2
- Where
- 13 sites in France
- Volunteers
- 59 people
- Sponsor
- AstraZeneca